Trial Profile
Comparison of Short- and Long-term Efficacy and Safety Between Ticagrelor and Clopidogrel in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms COSTIC
- 25 Nov 2021 Status changed from recruiting to completed.
- 10 Oct 2020 Planned End Date changed from 31 Dec 2020 to 31 Aug 2021.
- 10 Oct 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Aug 2021.